Quantcast
Last updated on April 24, 2014 at 1:21 EDT

Latest Transplant rejection Stories

2011-08-04 16:54:49

Findings by UT Southwestern Medical Center researchers may suggest new strategies for successful donor adult stem cell transplants in patients with blood cancers such as leukemia, lymphoma and myeloma. The study, published Aug. 5 in Cell Stem Cell, showed for the first time that adult blood stem cells can be regulated to overcome an immune response that leads to transplant rejection. It also opens up further studies in stem cell immunology, said Dr. Chengcheng "Alec" Zhang, assistant...

2011-08-04 14:05:43

New research finds that growing blood stem cells in the laboratory for about a week may help to overcome one of the most difficult roadblocks to successful transplantation, immune rejection. The study, published by Cell Press in the August issue of the journal Cell Stem Cell, may lead to more promising therapeutic strategies for transplanting blood stem cells. Hematopoietic stem cells (HSCs) are cells that can give rise to all of the different types of blood cells. Transplantation of HSCs has...

2011-08-02 13:06:09

A national transplant policy change designed to give African-American patients greater access to donor kidneys has sliced in half the racial disparities that have long characterized the allocation of lifesaving organs, new Johns Hopkins research suggests. Before 2003, the researchers note, an African-American patient who joined the kidney transplant list on the same day as a white patient would have a 37 percent smaller chance than a white counterpart of getting a transplant. In recent years,...

2011-07-29 14:38:29

Combination of two immunosuppressive drugs led to less organ rejection, better organ health after transplant For the thousands of patients who receive kidney transplants in the United States each year, preventing organ rejection without compromising other aspects of health requires a delicate balance of medications. Immunosuppresive drugs that protect transplanted organs can also cause serious side effects, including compromising patients' immunity to infection, cancer, and other threats....

2011-07-28 07:22:03

(Ivanhoe Newswire) -- A new treatment for hard-to-match kidney transplant patients is providing dramatic survival benefits. According to the study, hard-to-match transplant candidates who receive a new treatment designed to make their bodies more accepting of incompatible organs are twice as likely to survive eight years after transplant surgery as those who stay on dialysis for years waiting for compatible organs. It's estimated that there is more than 20,000 hard-to-match transplant...

2011-07-25 08:06:00

ATLANTA, July 25, 2011 /PRNewswire/ -- Waters Corporation (NYSE: WAT) today announced that its MassTrak(TM) Immunosuppressants XE Kit is now CE-marked in accordance with the IVD Directive 98/79/EC, for the quantitative measurement of the immunosuppressive drugs tacrolimus (FK506;Prograf®) in liver and kidney transplant patients and everolimus (Certican®) in adult kidney and cardiac transplant patients from human whole blood samples as an aid in the...

2011-07-20 07:03:35

(Ivanhoe Newswire) "“ Avoiding kidney mismatching is beneficial in pediatric kidney transplant patients, however, the likelihood of finding a matching donor must be considered against the wait time for a possible donation, according to this study. "Although avoiding HLA [human leukocyte antigen; cell surface antigens that regulate host cell responses to transplanted cells] antigen mismatching has been shown to benefit long-term graft survival, it has raised concerns about disadvantaging...

2011-07-18 16:24:01

Avoiding HLA-DR mismatching appears to be beneficial in pediatric kidney transplant patients, however the likelihood of finding a matching donor must be considered against the wait time for a possible donation, according to a report in the July issue of Archives of Surgery, one of the JAMA/Archives journals. "Although avoiding HLA [human leukocyte antigen; cell surface antigens that regulate host cell responses to transplanted cells] antigen mismatching has been shown to benefit long-term...

2011-07-08 00:19:00

EAST HANOVER, N.J., July 8, 2011 /PRNewswire/ -- Novartis Pharmaceuticals Corporation ("Novartis") announced today Phase III trial results that showed more than one-third of patients taking Afinitor® (everolimus) tablets* experienced a 50% or greater reduction in the size of their subependymal giant cell astrocytomas (SEGAs), non-cancerous brain tumors associated with tuberous sclerosis complex (TSC)(1,2,6). This study, the largest prospective clinical trial to date...

2011-06-30 18:20:22

New research published in the Journal of Leukocyte Biology suggests that overexpressing the human programmed death ligand-1 molecule in pig artery endothelial cells induces human immune tolerance A sizzling genetic discovery by Chinese scientists may one day allow pig tissue to be transplanted successfully into humans. Their research presented in the Journal of Leukocyte Biology (http://www.jleukbio.org) represents a major step forward toward filling the shortage of vital organs for human...